成大醫院血液科臨床試驗
NCKUH Hematology Trial DashboardShowing 13 trials
Adults ≥18 with R/R CLL/SLL (not refractory to venetoclax), ≥1 prior therapy, active disease, ECOG 0–2, measurable disease burden, adequate organ function.
Adults >=18 with LGLL or eligible cytotoxic lymphoma, ECOG and disease-specific prior-therapy requirements, adequate organ/coagulation function, and reproductive precautions; disease must be evaluable per protocol response frameworks.
DSP-5336-101
R/R AML/ALL (± MLLr or NPM1m) with required disease/genomic confirmation; age >=18 (site exceptions), ECOG <=2, WBC below protocol threshold, adequate renal/hepatic function, life expectancy >=3 months, contraception/pregnancy requirements met.
DZ2022J0004
Adults (>=18) with histologically confirmed r/r PTCL subtype, ECOG 0–2, prior systemic therapy failure/intolerance (with subtype-specific prior-therapy requirements), transplant-ineligible
ELRISE MDS
Adults ≥18 with WHO 2016 MDS, IPSS-R very low/low/intermediate risk, BM blasts <5%, sEPO <500 U/L, RBC transfusion-dependent (2–6 units/8 wks), Hgb <11 g/dL, ECOG 0–2.
Adults with PMF/post-PV MF/post-ET MF, ECOG 0–2, TP53WT at randomization, ruxolitinib run-in response in suboptimal range, stable ruxolitinib dosing, protocol-defined hematologic/hepatic/renal function, and strict contraception requirements.
MANIFEST-3
Adults ≥18 with PMF or post-PV/ET MF (ICC 2022), DIPSS int-1 to high risk, JAKi-naive, spleen ≥450 cm3, TSS ≥15, platelets ≥100, ANC ≥1, blood blasts <5%, ECOG 0–2, adequate liver function.
MK1026-010
POLARIS-1
Adults ≥18 with newly diagnosed Ph+/BCR-ABL1+ ALL (2016 WHO), essentially treatment-naïve, ECOG ≤2, life expectancy ≥3 mo, adequate hepatic/renal/cardiac/coagulation function, agree to contraception.
POLARIS-2
Adults ≥18 with CML-CP after ≥2 TKIs (Part A) or T315I+ after ≥1 TKI with no other options (Part B), TKI failure/intolerance per ELN 2025, ECOG ≤2, adequate organ function and electrolytes.
Adult (>=18) R/R FL1-3a or MZL after >=1 prior systemic line incl anti-CD20; measurable disease; ECOG 0-2; adequate marrow/organ function; informed consent; questionnaire/visit compliance; lenalidomide precautions.
RENEW (KER-050-D301)
Adults ≥18; MDS by WHO 2016, IPSS-R very-low/low/intermediate risk; transfusion-dependent (≥4 RBC units/16 wks); refractory/intolerant or unlikely to respond to ESAs; <5% marrow blasts; ECOG 0–2.
TRIlogy-5
Adults ≥18 with measurable R/R multiple myeloma, 1–3 prior lines including an anti-CD38 antibody and lenalidomide, ECOG 0–2, adequate organ/marrow function, no prior BCMA/GPRC5D T-cell redirection.